Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.54 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8271691 | 0.80 | TRPA1 (0.41) | TRPA1ASIC3MTNR1ACYP1A2CYP3A4 | |
| SCHEMBL16650194 | 0.73 | KDM4E (0.40) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL8024180 | 0.72 | CYP2A6 (0.48) | TRPA1ASIC3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27243912 | 0.72 | MTNR1A (0.33) | TRPA1MTNR1ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16651640 | 0.72 | TRPA1 (0.40) | TRPA1MTNR1ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16651306 | 0.72 | ALDH1A1 (0.35) | TRPA1MTNR1ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7019368 | 0.72 | CCR1 (0.37) | TRPA1MTNR1ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL659278 | 0.72 | ASIC3 (0.51) | TRPA1ASIC3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12559307 | 0.71 | IRAK4 (0.46) | TRPA1MTNR1ATSHRMAPK1MAPT | |
| SCHEMBL658129 | 0.70 | ASIC3 (0.41) | TRPA1ASIC3CYP3A4MAOACYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11884680-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3640241-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-09-28 | — | — | EP | disclosed |
| US-10941160-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3640241-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10562915-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| WO-2015058160-A1 | BROMODOMAIN INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| EP-1086106-B1 | FUROPYRIDINE DERIVATIVES AND THEIR THERAPEUTICAL USE | DARWIN DISCOVERY LTD (GB) | 2003-08-20 | — | — | EP | disclosed |
| EP-1086106-A1 | FUROPYRIDINE DERIVATIVES AND THEIR THERAPEUTICAL USE | Darwin Discovery Limited (GB) | 2001-03-28 | — | — | EP | disclosed |
| US-6169090-B1 | FOR INHIBITION OF PHOSPHODIESTERASE IV | DARWIN DISCOVERY, LTD. (GB) | 2001-01-02 | — | — | US | disclosed |
| WO-1999064423-A1 | FUROPYRIDINE DERIVATIVES AND THEIR THERAPEUTICAL USE | DARWIN DISCOVERY LIMITED (GB) | 1999-12-16 | — | — | WO | disclosed |
| US-4808595-A | REDUCTION OF PRESSURE DUE TO GLAUCOMA | MERCK & CO., INC. (US) | 1989-02-28 | — | — | US | disclosed |
| EP-0271273-A2 | Thieno-and furopyridine sulfonamides | MERCK & CO. INC. (US) | 1988-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562915-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | TRPA1 4826/4885ASIC3 4264/4885MTNR1A 3834/4885 |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | TRPA1 4826/4885ASIC3 4264/4885MTNR1A 3834/4885 |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | TRPA1 4826/4885ASIC3 4264/4885MTNR1A 3834/4885 |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | TRPA1 4826/4885ASIC3 4264/4885MTNR1A 3834/4885 |
| US-10941160-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | TRPA1 4826/4885ASIC3 4264/4885MTNR1A 3834/4885 |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | TRPA1 4826/4885ASIC3 4264/4885MTNR1A 3834/4885 |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | TRPA1 4826/4885ASIC3 4264/4885MTNR1A 3834/4885 |
| US-11884680-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | TRPA1 4826/4885ASIC3 4264/4885MTNR1A 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.